226 related articles for article (PubMed ID: 37551951)
1. Update on bi-specific monoclonal antibodies for blood cancers.
Shouse G
Curr Opin Oncol; 2023 Sep; 35(5):441-445. PubMed ID: 37551951
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibodies in indolent B-cell lymphomas.
Radhakrishnan VS; Davies AJ
Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
Li X; Zhang P; Sun H; Han L; Jiang Z; Yu J
Expert Opin Biol Ther; 2023; 23(12):1193-1195. PubMed ID: 37852928
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
González Barca E
Front Immunol; 2022; 13():909008. PubMed ID: 35928819
[TBL] [Abstract][Full Text] [Related]
6. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
Liu X; Zhao J; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
[TBL] [Abstract][Full Text] [Related]
7. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
Matarasso S; Assouline S
Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
[TBL] [Abstract][Full Text] [Related]
8. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
9. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR
Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732
[No Abstract] [Full Text] [Related]
10. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T
Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901
[TBL] [Abstract][Full Text] [Related]
11. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma.
Cassanello G; Luna de Abia A; Falchi L
Oncoimmunology; 2024; 13(1):2321648. PubMed ID: 38445082
[TBL] [Abstract][Full Text] [Related]
12. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
Yamaguchi M
Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
[TBL] [Abstract][Full Text] [Related]
13. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies in the treatment of lymphoid malignancies.
Tsirigotis P; Economopoulos T
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):267-71. PubMed ID: 17935974
[TBL] [Abstract][Full Text] [Related]
15. [Drug approval: Mosunetuzumab - third-line therapy in follicular lymphoma].
Gondran C; Ysebaert L
Bull Cancer; 2022 Nov; 109(11):1105-1106. PubMed ID: 36167561
[No Abstract] [Full Text] [Related]
16. Pharmacist perspectives on emerging T cell-engaging bispecific therapies in cancer therapeutics.
Moore DC; Digiantonio N; Oxencis CJ; Taucher KD
Am J Health Syst Pharm; 2024 Feb; ():. PubMed ID: 38394329
[TBL] [Abstract][Full Text] [Related]
17. Mosunetuzumab: First Approval.
Kang C
Drugs; 2022 Jul; 82(11):1229-1234. PubMed ID: 35947358
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.
Polgarova K; Trneny M
Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755
[TBL] [Abstract][Full Text] [Related]
19. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
20. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
